Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT

Turku University Hospital30 enrolled

Overview

The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Glioma

Interventions

[68Ga]DOTATOCDRUG

120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age: 18 to 70 years old * Language spoken: Finnish or Swedish * Performance status: Karnofsky score 70 or better or WHO performance status 2 or better * Supratentorial malignant glioma based on MRI imaging * Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging * Patients must be able to understand the meaning of the study and sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff Exclusion Criteria: * Any medical or psychiatric condition that compromises the subject´s ability to participate in the study * Any other significant disease including liver or renal disease * Pregnant or lactating women

Locations (1)

Turku PET Centre, Turku University Hospital

Turku, Finland

Outcomes

Primary Outcomes

Malignant glioma uptake of 68Ga-DOTATOC

PET/CT imaging of the brain starts immediately after the intravenous bolus injection of 68Ga-DOTATOC. Dynamic PET/CT imaging is done over 60-min. A late 90-min scan will be obtained for selected patients. PET studies are analyzed by determining the Standardized Uptake Values (SUV) of the tumor using regions of interest (ROI) drawn both manually and automatically on the tumor.

Time frame: within 90 minutes post-injection

Secondary Outcomes

Immunohistochemical SST2 receptor status of the tumor specimen

Time frame: After glioma surgery within 4 weeks of PET/CT imaging

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.